General Biologicals Corp.

As of June 30, 2026, General Biologicals Corp. carries a market capitalization of 814.11M, placing it among publicly traded companies globally. Its enterprise value stands at 2.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, General Biologicals Corp. has 70.79M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, General Biologicals Corp. maintains a current ratio of 1.57, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, General Biologicals Corp.'s stock has declined approximately 52.75% over the past 52 weeks. The 50-day moving average sits at 9.01, while the 200-day moving average is 11.59.

As of June 30, 2026, General Biologicals Corp. holds 604.26M in cash and equivalents against 2.53B in total debt, resulting in a net debt position of 1.91B. Total book value stands at 796.45M, with working capital of 285.73M providing operational flexibility.

General Biologicals Corp.'s most recent stock split took place on September 8, 2025 with a 613:634 split ratio.